SMART技术保护记忆环路的脑转移瘤放疗剂量学研究
该回顾性研究对101例接受单次LINAC单等中心SRS的脑转移患者行记忆环路各亚结构勾画与剂量评估,发现≥10个病灶者记忆环路Dmean、Dmedian、Dmax均显著高于单发转移者;对13例≥10个病灶者采用SMART技术再优化,在维持PTV V100%>95%前提下显著降低记忆环路Dmean、Dmedian、Dmax及D100剂量,提示SMART临床可行。
要点
- ≥10个脑转移灶者记忆环路Dmean为2.9 Gy,显著高于单发者的0.41 Gy。
- SMART再优化后记忆环路Dmean由2.9 Gy降至1.8 Gy(p=0.0001)。
- SMART在维持PTV V100%>95%的同时降低记忆环路剂量。
核心结论
- 脑转移灶数目增加导致记忆环路剂量升高,≥10个病灶者Dmean、Dmedian、Dmax均高于<10个病灶者。
- SMART技术在临床可行,可在维持>95% PTV覆盖(V100%>95%)的前提下降低记忆环路剂量。
- SMART是否带来神经认知获益尚需进一步研究评估。
研究设计与样本
- 回顾性研究,对101例接受单次、基于直线加速器(LINAC)、单等中心SRS计划的脑转移患者行记忆环路亚结构勾画。
- 按脑转移数目分为1个、2-4个、5-9个和≥10个四组。
- 对≥10个病灶者(n=13)用SMART再优化,最大化降低记忆环路剂量并维持PTV V100%>95%。
主要发现
- ≥10个脑转移灶者记忆环路Dmean为2.9 Gy,单发者为0.41 Gy(p<0.0001)。
- ≥10个脑转移灶者记忆环路Dmedian为2.9 Gy,单发者为0.34 Gy(p<0.0001)。
- ≥10个脑转移灶者记忆环路Dmax为9.0 Gy,单发者为1.9 Gy(p<0.0001)。
关键数值与推荐
- SMART再优化后记忆环路Dmean由2.9 Gy降至1.8 Gy(p=0.0001)。
- SMART再优化后记忆环路Dmedian由2.9 Gy降至1.8 Gy(p=0.0002)。
- SMART再优化后记忆环路Dmax由9.0 Gy降至4.7 Gy(p=0.0007)。
- SMART再优化后记忆环路D100由1.5 Gy降至0.98 Gy(p=0.0010)。
- SMART再优化要求维持PTV V100%>95%。
临床怎么用
- 对多发性脑转移(尤其≥10个病灶)行SRS计划时应关注记忆环路受量。
- SMART技术可作为在保证PTV覆盖前提下降低记忆环路剂量的可行优化策略。
局限性
- 研究为回顾性设计,SMART再优化仅纳入13例≥10个病灶患者。
- 研究评估的是剂量学指标,未报告神经认知结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation dose reduction to major memory circuit substructures (e.g., hippocampus, amygdala, fornix, and corpus callosum) may reduce patients' neurocognitive toxicities. We evaluated memory circuit (MC) dosimetry and determined the feasibility of the "Sparing Memory with Advanced Radiosurgery Targeting" (SMART) technique in patients with brain metastases. MATERIALS AND METHODS: Retrospective contouring of MC substructures was performed for 101 patients that received single-fraction, linear accelerator (LINAC)-based, monoisocentric SRS plans for increasing numbers of brain metastases: 1, 2-4, 5-9 and ≥ 10. Patients with ≥10 lesions (n = 13) were reoptimized using SMART by maximizing dose reduction to MC while maintaining >95% PTV coverage (V100% > 95%). Dosimetric parameters such as Dmean, Dmax, and Dmedian to MC, cumulative PTV and MC volume were evaluated. RESULTS: Patients with ≥10 brain metastases received significantly higher Dmean (2.9 vs. 0.41 Gy, p < 0.0001), Dmedian (2.9 vs. 0.34 Gy, p < 0.0001) and Dmax (9.0 vs. 1.9 Gy, p < 0.0001) to the MC compared to those with a single metastasis. SMART replanning yielded a significant decrease in Dmean, Dmedian, Dmax, and D100 doses to the MC when compared to clinical dosimetry (2.9 vs. 1.8 Gy, p = 0.0001; 2.9 vs. 1.8 Gy, p = 0.0002; 9.0 vs. 4.7 Gy, p = 0.0007; 1.5 vs. 0.98 Gy, p = 0.0010, respectively). CONCLUSION: Increased number of brain metastases results in higher MC doses. Patients with ≥10 lesions received increased Dmean/Dmedian/Dmax doses to the MC compared to patients with <10 brain metastases. SMART technique is clinically feasible. Studies evaluating the neurocognitive benefits of SMART are warranted.
引用
- Lo N, Wadi-Ramahi S, Wang H, et al. Memory circuit dosimetry in patients with brain metastases treated with Sparing Memory with Advanced Radiosurgery Targeting (SMART) technique. Clin Transl Radiat Oncol. 2026. PMID: 42668550. doi:10.1016/j.ctro.2026.101267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。